Reply

Journal of the American College of Surgeons

Volumn 206, Issue 1, 2008, Pages 199-200

  Chapman, Will ^a   Weaver, Fred ^a   Alexander, Allan ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5; THROMBIN; THROMBIN ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; DRUG EFFICACY; DRUG SAFETY; HEMOSTASIS; HUMAN; IMMUNE RESPONSE; INCIDENCE; LETTER; MOLECULAR WEIGHT; NONHUMAN; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; THROMBOSIS;

EID: 37249051764     PISSN: 10727515     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jamcollsurg.2007.10.010     Document Type: Letter

References (4)

1. Chapman W.C., Singla N., Genyk Y., et al. A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human and bovine thrombin in surgical hemostasis. J Am Coll Surg 205 (2007) 256-265
2. Ortel T.L., Charles L.A., Keller F.G., et al. Topical thrombin and acquired coagulation factor inhibitors: clinical spectrum and laboratory diagnosis. Am J Hematol 45 (1994) 128-135
3. Ortel T.L., Mercer M.C., Thames E.H., et al. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg 233 (2001) 88-96
4. Lawson J.H. The clinical use and immunologic impact of thrombin in surgery. Semin Thromb Hemost 32 suppl 1 (2006) 98-110